Supplementary Data from Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer

Abstract

Table S1, Table S2, Figure S1 (A)(B)(C)(D)and Figure S2(A)(B)